Back to search results
NCT05286736

Neuroplasticity in Parkinson's Disease

Active, Not Recruiting
Not specifiedAges 21–75Observational
University of Minnesota
~50 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:NeuroimagingQuantitative assessments

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in volume of Subthalamic Nucleus
Measured over Baseline, 30-36 months
+9 more outcomes measured

Conditions

Parkinson
Parkinson Disease

Explore related trials

Parkinson Disease

NCT05286736

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Minnesota

    Minneapolis, Minnesotano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
Not receiving levodopa or dopamine agonist to treat PD (at baseline)
Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
Age- (+/- 3 years) and sex-matched to participants with PD
Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters

Exclusion

Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
Other significant neurological disorders that may affect participation or performance in the study
Implanted DBS or other neurosurgeries to treat PD
Pregnancy
History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.
Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
Pacemaker or any implanted device
History of surgery on blood vessels, brain, or heart
Unexplained, recurring headaches or concussion within the last six months
Severe hearing impairment

What this trial measures

  • Change in volume of Subthalamic NucleusBaseline, 30-36 months

    The volume of the subthalamic nucleus is assessed using MRI and reported in millimeters cubed (mm\^3).

  • Change in fractional Anisotropy of Subthalamic NucleusBaseline, 30-36 months

    Fractional anisotropy, measured using MRI, is a unit-less value between zero and one that describes the degree of anisotropy of water diffusion in a specified brain area. Higher values indicate a greater degree of anisotropy, while a score of zero indicates isotropic diffusion.

  • Change in cortico-STN ConnectivityBaseline, 30-36 months

    Cortico-Subthalamic nucleus connectivity is measured using MRI and reported as a z score (unitless).

  • Change in paired Associative Stimulation-Motor Evoked Potential (PAS-MEP)Baseline, 30-36 months

    Motor evoked potential is measured as the amplitude of change in target muscle electrical activity following transcranial magnetic stimulation (TMS) and reported in units of millivolts (mV).

  • Change in Mattis Dementia Rating Scale 2 (DRS-2)Baseline, 30-36 months

    The DRS-2 consists of 24 items, rated on a scale from 0 to 6. Item scores are combined into five subscales: attention (8 items), initiation/perseveration (11 items), construction (6 items), conceptualization ( 6 items), and memory (5 items). These five subscale scores are summed to calculate a total score ranging from from 0 to 144 points, with lower scores indicating worse performance due to dementia.

  • Change in Rey Complex Figure and Matrix Reasoning of the Wechsler Adult Intelligence Scale - IVBaseline, 30-36 months
  • Change in Stroop Color Word TestBaseline, 30-36 months
  • Change in Wisconsin Card Sorting TestBaseline, 30-36 months
  • Change in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency SubtestBaseline, 30-36 months
  • Change in Brief Visuospatial Memory Test - Revised (BVMT-R)Baseline, 30-36 months